DDInter1543 DDInter927
Protriptyline hydrochloride is a dibenzocycloheptene-derivative tricyclic antidepressant (TCA). TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, protriptyline does not affect mood or arousal, but may cause sedation. In depressed individuals, protriptyline exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. In addition, TCAs down-regulate cerebral cortical &beta;-adrenergic receptors and sensitize post-synaptic serotonergic receptors with chronic use. The antidepressant effects of TCAs are thought to be due to an overall increase in serotonergic neurotransmission. TCAs also block histamine H<sub>1</sub> receptors, alpha<sub>1</sub
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Protriptyline {u} (Compound) resembles {v} (Compound) Maprotiline
Protriptyline {u} (Compound) resembles {v} (Compound) Cyclobenzaprine
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cyproheptadine
Protriptyline {u} (Compound) binds {v} (Gene) CYP2D6
Protriptyline {u} (Compound) upregulates {v} (Gene) MAP7
Protriptyline {u} (Compound) downregulates {v} (Gene) NUP93
Protriptyline {u} (Compound) causes {v} (Side Effect) Parotid swelling
Protriptyline {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Protriptyline {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Protriptyline {u} may lead to a major life threatening interaction when taken with {v} Pasireotide
Protriptyline (Compound) resembles Maprotiline (Compound)
Protriptyline (Compound) resembles Cyclobenzaprine (Compound)
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cyproheptadine
Protriptyline (Compound) binds CYP2D6 (Gene)
Protriptyline (Compound) upregulates MAP7 (Gene)
Protriptyline (Compound) downregulates NUP93 (Gene)
Protriptyline (Compound) causes Parotid swelling (Side Effect)
Protriptyline may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Protriptyline may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Protriptyline may lead to a major life threatening interaction when taken with Pasireotide